Beranda › Melanoma › Florida › Orlando
Uji klinis Melanoma di Orlando, FL
15 studi untuk Melanoma mencari peserta di lokasi sekitar Orlando (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee · 16 mi jauhnya
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Menerima pesertaFase 3
- Orlando Health Cancer Institute, Orlando
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
Menerima pesertaFase 2
- Nemours Children's Hospital, Orlando
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
Menerima pesertaFase 3
- Orlando Health Cancer Institute, Orlando
- Health Central, Ocoee · 10 mi jauhnya
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Menerima pesertaFase 1
- AdventHealth, Orlando
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Menerima pesertaFase 2
- Orlando Health Cancer Institute, Orlando
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute - Florida Cancer Specialists, Orlando
Project: Every Child for Younger Patients With Cancer
Menerima pesertaStudi observasional
- AdventHealth Orlando, Orlando
- Arnold Palmer Hospital for Children, Orlando
- Nemours Children's Hospital, Orlando
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- AdventHealth Celebration, Celebration · 17 mi jauhnya
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Menerima pesertaFase 1/2
- Clermont Oncology Center, Clermont · 24 mi jauhnya
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Menerima pesertaFase 1
- Florida Cancer Specialists - Lake Nona, Orlando
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Menerima pesertaFase 1/2
- Orlando Health Cancer Institute (Melanoma/NSCLC), Orlando
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Menerima pesertaFase 1/2
- Orlando Health Cancer Institute, Orlando
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Menerima pesertaFase 3
- Orlando Health Cancer Institute, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · 17 mi jauhnya
Uji klinis Melanoma di kota lain
- Houston, TX59 studi
- New York City, NY38 studi
- Los Angeles, CA34 studi
- Nashville, TN33 studi
- Pittsburgh, PA31 studi
- Boston, MA26 studi
- Philadelphia, PA23 studi
- San Francisco, CA22 studi
- Durham, NC21 studi
- Atlanta, GA21 studi
- St. Louis, MO21 studi
- Salt Lake City, UT21 studi
Studi lain di Orlando
- Kanker Paru Non-Sel Kecil44 studi
- Obesitas31 studi
- Kanker Metastatik29 studi
- Kelebihan Berat Badan27 studi
- Penyakit Alzheimer25 studi
- Diabetes Tipe 224 studi
- Kanker (semua jenis)24 studi
- Kanker Payudara23 studi
- Kanker Ovarium22 studi
- Kolitis Ulseratif22 studi
- Kanker Paru21 studi
- Kanker Kolorektal19 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.